China Newsletter | Q1 2025/Issue No. 63

In This Issue

This China Newsletter provides an overview of key Q1 2025 developments in the following areas:
 

1.

Antitrust

• China Unveils Anti-Monopoly Guidelines for Pharmaceutical Sector

2.

Compliance

• China Formally Finalizes First Anti-Corruption Guidelines for the Health Care and Life Sciences Industry

3.

Corporate

• China Streamlines Company Registration: Key Changes Effective February 2025

4.

Data Privacy & Cybersecurity

• China Issues Personal Information Compliance Audit Rule
   
• China Issues Regulation for Facial Recognition Technology Applications
   
• China Issues Measures for Labeling AI-Generated and Synthetic Content

5.

Foreign Investment

• China Publishes 2025 Action Plan for Stabilizing Foreign Investment

6.

International Trade

• China Promulgates Regulations for Implementing Anti-Foreign Sanctions Law

Read the Full Newsletter Here